GlassScriptPhysician profile
Tracie Thornton
NPI 1467962472
$9,696.07
in general payments reported to CMS, 2019-2025
60 companies · $2,557 in 2025
The $2,557 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,293 · 2022: $149 · 2023: $1,936 · 2024: $2,761 · 2025: $2,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,813 · Education: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,812.99 |
| Education | $440.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,022.21 | 2021-2025 | Imfinzi, Calquence, Lynparza |
| Janssen Biotech, INC. | $755.51 | 2021-2025 | Darzalex, Talvey, Tecvayli |
| Incyte Corporation | $649.41 | 2021-2025 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $633.15 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Novartis Pharmaceuticals Corporation | $612.28 | 2021-2025 | |
| Pfizer INC. | $591.27 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $457.52 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Seagen INC. | $441.47 | 2021-2025 | Adcetris, Tukysa, Padcev |
| Celgene Corporation | $289.55 | 2021-2025 | Reblozyl |
| Astellas Pharma US INC | $280.95 | 2023-2025 | Xtandi |
| Amgen INC. | $228.93 | 2021-2023 | Vectibix, Xgeva, Nplate |
| Array Biopharma INC | $220.74 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Pharmaessentia USA Corporation | $214.51 | 2023-2025 | Besremi |
| Lilly USA, LLC | $210.12 | 2021-2024 | Jaypirca, Verzenio, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $182.38 | 2023-2025 | Ninlaro, Fruzaqla |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $180.61 | 2021-2025 | |
| Sobi, INC | $162.18 | 2023-2025 | |
| Glaxosmithkline, LLC. | $157.97 | 2021-2024 | Zejula, Jemperli, Ojjaara |
| Pharmacyclics LLC, An Abbvie Company | $153.79 | 2021-2023 | Imbruvica |
| Stemline Therapeutics INC. | $151.67 | 2024-2025 | Orserdu |
| Daiichi Sankyo INC. | $138.76 | 2021-2025 | Enhertu, Datroway |
| Beone Medicines USA, INC. | $129.48 | 2025 | Brukinsa, Tevimbra |
| Regeneron Healthcare Solutions, INC. | $127.64 | 2021-2025 | Libtayo |
| Beigene USA, INC. | $102.52 | 2023-2025 | Brukinsa |
| Abbvie INC. | $100.28 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $94.39 | 2021-2023 | Zepzelca |
| Gilead Sciences, INC. | $89.50 | 2021-2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $88.37 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Pharmacosmos Therapeutics INC. | $85.52 | 2021-2025 | Monoferric |
| Ipsen Biopharmaceuticals, INC | $81.59 | 2024-2025 | Onivyde, Somatuline Depot |
| Progenics Pharmaceuticals, INC. | $80.05 | 2021-2024 | Pylarify |
| Kite Pharma, INC. | $74.31 | 2023-2025 | Yescarta |
| Emd Serono, INC. | $73.37 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $61.23 | 2023-2025 | Orgovyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.26 | 2021-2023 | Gilotrif |
| Servier Pharmaceuticals LLC | $48.61 | 2023-2025 | |
| Blueprint Medicines Corporation | $48.22 | 2024-2025 | Ayvakit |
| Genzyme Corporation | $45.64 | 2021-2023 | |
| Mirati Therapeutics, INC. | $43.85 | 2023 | Krazati |
| Immunocore Limited | $43.66 | 2025 | Kimmtrak |
| Genentech USA, INC. | $41.59 | 2024-2025 | Columvi, Lunsumio, Polivy |
| Alexion Pharmaceuticals, INC. | $38.35 | 2023 | Ultomiris |
| Recordati_rare_diseases_inc. | $37.35 | 2021-2025 | Sylvant |
| Karyopharm Therapeutics INC. | $35.03 | 2021-2023 | Xpovio |
| Dendreon Pharmaceuticals LLC | $32.30 | 2025 | Provenge |
| Puma Biotechnology, INC. | $31.99 | 2021-2025 | |
| Exelixis INC. | $29.15 | 2025 | Cabometyx |
| Ge Healthcare | $25.00 | 2025 | |
| Amag Pharmaceuticals, INC. | $21.52 | 2021 | |
| Deciphera Pharmaceuticals INC. | $21.24 | 2024 | Qinlock |
| Agios Pharmaceuticals, INC. | $20.81 | 2025 | Pyrukynd |
| Fennec Pharmaceuticals, INC. | $20.52 | 2025 | Fyarro |
| Kyowa Kirin, INC. | $20.10 | 2023 | Poteligeo |
| Taiho Oncology, INC. | $19.47 | 2023 | |
| Aveo Pharmaceuticals, INC. | $18.73 | 2023 | Fotivda |
| Global Blood Therapeutics, INC. | $16.75 | 2021 | |
| Myriad Genetic Laboratories, INC. | $16.51 | 2023 | Bracanalysis Cdx |
| Coherus Oncology, INC. | $13.82 | 2021 | |
| Spectrum Pharmaceuticals INC. | $13.64 | 2023 | Rolvedon |
| Acceleron Pharma, INC. | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracie Thornton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.